CRX Cyprotex

TIDMCRX

RNS Number : 9373L

Cyprotex PLC

06 October 2016

Cyprotex PLC

("Cyprotex" or "the Company")

Conversion of Loan Notes & Total Voting Rights

Cyprotex PLC (AIM: CRX), the drug discovery technology and information company, today announces that it has issued 40,702 new ordinary shares of 1p each ("new Ordinary Shares") pursuant to the conversion of Convertible Loan Notes.

The issue of these new Ordinary Shares is subject to the new Ordinary Shares being admitted to trading on AIM, application for which has been made. Trading in the new Ordinary Shares, which will rank pari passu in all respects with the existing ordinary shares, is expected to commence on 12 October 2016.

Total Voting Rights

Following the issue of the 40,702 new Ordinary Shares on 12 October 2016, the Company will have a total of 22,509,042 Ordinary Shares in issue and one voting right per Ordinary Share.

The above figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

The above information is provided by the Company in accordance with its obligations under the FCA's Disclosure and Transparency Rules.

For further information:

 
 Cyprotex PLC                         Tel: +44 (0) 1625 
                                       505 100 
 Dr Anthony Baxter, Chief Executive   ir@cyprotex.com 
  Officer                              www.cyprotex.com 
  John Dootson, Chief Financial 
  Officer 
  Mark Warburton, Chief Operating 
  Officer and Legal Counsel 
 
 N+1 Singer (Nomad & Broker)          Tel: +44 (0)20 7496 
                                       3000 
 Shaun Dobson                         shaun.dobson@n1singer.com 
  Jen Boorer                           jennifer.boorer@n1singer.com 
                                       www.n1singer.com 
 

Notes to Editors

About Cyprotex PLC

Cyprotex is quoted on the AIM market of the London Stock Exchange (CRX). It has sites at Macclesfield and Alderley Park, both of which are near Manchester in the UK, and at Watertown, MA and Kalamazoo, MI in the US. The Company was established in 1999 and works with more than 1500 partners within the pharmaceutical and biotech industry, cosmetics and personal care industry and the chemical industry. Cyprotex acquired Apredica and the assets of Cellumen Inc. in August 2010 and the combined business provides support for a wide range of experimental and computational ADME-Tox and PK services. The acquisition of the assets and business of CeeTox in January 2014 has enabled Cyprotex to expand its range of services to target the personal care, cosmetics and chemical industries. In 2015, Cyprotex launched its new bioscience division to expand its capabilities into phenotypic and target based screening. The Company's core capabilities include high quality in vitro ADME services, mechanistic toxicology and high content toxicology screening services, including our proprietary CellCiphr(R) toxicity prediction technology, bioscience services, predictive modelling solutions including Cloe(R) PK, chemPK(TM) and chemTox, and a range of skin, ocular and endocrine disruption services. For more information, please visit www.cyprotex.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

CONAKADDABDDQKK

(END) Dow Jones Newswires

October 06, 2016 12:15 ET (16:15 GMT)

Cyprotex (LSE:CRX)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024

Cyprotex (LSE:CRX)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024